MA25820A1 - Combinaisons d'inhibiteurs de peptidase iv de dipeptidyle et d'autres agents antidiabetiques pour le traitement du mellitus de diabete. - Google Patents

Combinaisons d'inhibiteurs de peptidase iv de dipeptidyle et d'autres agents antidiabetiques pour le traitement du mellitus de diabete.

Info

Publication number
MA25820A1
MA25820A1 MA26965A MA26965A MA25820A1 MA 25820 A1 MA25820 A1 MA 25820A1 MA 26965 A MA26965 A MA 26965A MA 26965 A MA26965 A MA 26965A MA 25820 A1 MA25820 A1 MA 25820A1
Authority
MA
Morocco
Prior art keywords
inhibitors
combinations
treatment
diabetes mellitus
dipeptidyl peptidase
Prior art date
Application number
MA26965A
Other languages
English (en)
Inventor
Dr Jonathan Robert Sander Arch
James Martin Lenhard
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of MA25820A1 publication Critical patent/MA25820A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA26965A 2000-06-19 2002-12-18 Combinaisons d'inhibiteurs de peptidase iv de dipeptidyle et d'autres agents antidiabetiques pour le traitement du mellitus de diabete. MA25820A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0014969.0A GB0014969D0 (en) 2000-06-19 2000-06-19 Novel method of treatment

Publications (1)

Publication Number Publication Date
MA25820A1 true MA25820A1 (fr) 2003-07-01

Family

ID=9893956

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26965A MA25820A1 (fr) 2000-06-19 2002-12-18 Combinaisons d'inhibiteurs de peptidase iv de dipeptidyle et d'autres agents antidiabetiques pour le traitement du mellitus de diabete.

Country Status (29)

Country Link
US (2) US7241756B2 (fr)
EP (2) EP2036554A1 (fr)
JP (1) JP2003535898A (fr)
KR (1) KR20030019440A (fr)
CN (1) CN1443068A (fr)
AP (1) AP2002002703A0 (fr)
AT (1) ATE419850T1 (fr)
AU (3) AU2001264148A1 (fr)
BG (1) BG107385A (fr)
BR (1) BR0111800A (fr)
CA (1) CA2413299A1 (fr)
CZ (1) CZ20024069A3 (fr)
DE (1) DE60137329D1 (fr)
DZ (1) DZ3390A1 (fr)
EA (1) EA200300036A1 (fr)
EC (1) ECSP024397A (fr)
GB (1) GB0014969D0 (fr)
HR (1) HRP20020994A2 (fr)
HU (1) HUP0301194A3 (fr)
IL (2) IL153529A0 (fr)
MA (1) MA25820A1 (fr)
MX (1) MXPA02012763A (fr)
NO (1) NO20026038L (fr)
OA (1) OA12295A (fr)
PL (1) PL360493A1 (fr)
SK (1) SK17832002A3 (fr)
WO (1) WO2001097808A1 (fr)
YU (1) YU1703A (fr)
ZA (1) ZA200300203B (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
GB0109146D0 (en) * 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
KR20040015298A (ko) 2001-06-27 2004-02-18 스미스클라인 비참 코포레이션 디펩티딜 펩티다제 억제제로서의 플루오로피롤리딘
WO2003002595A2 (fr) * 2001-06-27 2003-01-09 Probiodrug Ag Nouveaux inhibiteurs de dipeptidylpeptidase iv et leurs utilisations en tant qu'agents anti-cancereux
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
KR20040095241A (ko) 2002-02-28 2004-11-12 프로시디온 리미티드 글루타미닐계 ｄｐｉｖ 억제제
AU2007203210B2 (en) * 2002-05-29 2009-10-01 Novartis Ag Combination of a DPP IV inhibitor and a cardiovascular compound
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
CA2496249C (fr) * 2002-08-21 2012-01-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, leur production et leur utilisation comme medicament
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ATE461212T1 (de) * 2002-09-18 2010-04-15 Prosidion Ltd Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv)
MXPA05003252A (es) * 2002-09-26 2005-07-05 Eisai Co Ltd Farmaco de combinacion.
EP1608317B1 (fr) 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyle peptidase
EP1638554A1 (fr) * 2003-06-27 2006-03-29 Dr. Reddy's Research Foundation Compositions comprenant de la balaglitazone et d'autres composes antidiabetiques
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7579357B2 (en) 2003-08-13 2009-08-25 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
CN1292747C (zh) * 2003-09-16 2007-01-03 广东省心血管病研究所 一种用于治疗高血压的复方制剂
DK1675578T3 (da) 2003-10-15 2013-08-26 Probiodrug Ag Inhibitorer af glutaminyl- og glutamatcyclaser til behandling af de neurodegenerative sygdomme FBD og FDD
EP1677757A2 (fr) * 2003-10-31 2006-07-12 Alza Corporation Compositions et formes posologiques permettant une absorption amelioree
MXPA06005518A (es) 2003-11-17 2006-08-17 Novartis Ag Uso de inhibidores de la dipeptidil peptidasa iv.
ES2684325T5 (es) 2004-01-20 2024-06-10 Novartis Ag Formulación y proceso de compresión directa
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
EP1753730A1 (fr) 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
WO2006019965A2 (fr) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Inhibiteurs de la dipeptidyl peptidase
US20070259927A1 (en) * 2004-08-26 2007-11-08 Takeda Pharmaceutical Company Limited Remedy for Diabetes
AU2005299808B2 (en) * 2004-10-25 2009-08-20 Novartis Ag Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
JP2008115080A (ja) * 2005-04-22 2008-05-22 Taisho Pharmaceutical Co Ltd 併用医薬
CN102210865A (zh) * 2005-06-03 2011-10-12 田边三菱制药株式会社 伴随的药物试剂及其用途
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ZA200802857B (en) 2005-09-14 2009-09-30 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
JP5072848B2 (ja) * 2005-09-20 2012-11-14 ノバルティス アーゲー 低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
JP5165582B2 (ja) * 2005-12-16 2013-03-21 メルク・シャープ・エンド・ドーム・コーポレイション ジペプチジルペプチダーゼ−４インヒビターとメトホルミンとを組み合わせた医薬組成物
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
RU2438671C2 (ru) * 2005-12-28 2012-01-10 Такеда Фармасьютикал Компани Лимитед Терапевтическое средство против диабета
ZA200806143B (en) * 2005-12-28 2009-11-25 Takeda Pharmaceutical Therapeutic agent for diabetes
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JP5284968B2 (ja) * 2007-02-01 2013-09-11 武田薬品工業株式会社 アログリプチンおよびピオグリタゾンを含有する固形製剤
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
ES2603879T3 (es) 2007-07-19 2017-03-01 Takeda Pharmaceutical Company Limited Preparación sólida que comprende alogliptina e hidrocloruro de metformina
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2146210A1 (fr) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
WO2009128360A1 (fr) * 2008-04-18 2009-10-22 大日本住友製薬株式会社 Agent thérapeutique pour le diabète
JP4643760B2 (ja) * 2008-05-14 2011-03-02 株式会社三和化学研究所 Ｄｐｐ−ｉｖ阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (ko) * 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013508370A (ja) * 2009-10-23 2013-03-07 メルク・シャープ・エンド・ドーム・コーポレイション ジペプチジルペプチダーゼ−４阻害剤とピオグリタゾンとの組み合わせの医薬組成物
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
EP3725325B1 (fr) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Traitement du diabète
CA2812061A1 (fr) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulateurs du recepteur gpr119 et traitement des troubles qui lui sont lies
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2012135570A1 (fr) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (fr) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (fr) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
TW201513857A (zh) * 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
EP3110449B1 (fr) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Utilisation médicale d'un inhibiteur de dpp-4
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.
WO2018162722A1 (fr) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Inhibiteurs de dpp-4 à utiliser dans le traitement de fractures osseuses
EP3606527A1 (fr) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Agoniste de ppar-gamma pour le traitement de la paralysie supranucléaire progressive
CN115109161B (zh) * 2022-06-28 2023-08-11 广东赛尔生物科技有限公司 含有间充质干细胞的减肥药物组合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (fr) 1988-03-08 1989-09-21 Pfizer Inc. Derives de thiaxolidinedione hypoglycemiques
WO1991007107A1 (fr) 1989-11-13 1991-05-30 Pfizer Inc. Agents d'oxazolidinedione hypoglycemiques
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
HUT65619A (en) 1990-07-03 1994-07-28 Yamanouchi Pharma Co Ltd Process for producing bisheterocyclic compounds and pharmaceutical preparations containing them
US5334604A (en) 1990-08-23 1994-08-02 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
CZ196693A3 (en) 1991-04-11 1994-05-18 Upjohn Co Thiazolidinedione derivatives, and process for preparing thereof
TW222626B (fr) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
AU3959193A (en) 1992-04-10 1993-11-18 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type II-diabetes
WO1993022445A1 (fr) 1992-05-05 1993-11-11 The Upjohn Company Procede de production de metabolites de pioglitazone
AU678974B2 (en) 1992-07-03 1997-06-19 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
AU4721897A (en) 1996-10-25 1998-05-22 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline derivatives
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
US6274608B1 (en) * 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
SK8902002A3 (en) * 1999-12-23 2002-11-06 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
EP1741447B1 (fr) * 2000-01-21 2013-09-18 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) * 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus

Also Published As

Publication number Publication date
EP1292300B1 (fr) 2009-01-07
ZA200300203B (en) 2004-03-26
CN1443068A (zh) 2003-09-17
HUP0301194A3 (en) 2007-09-28
IL153529A0 (en) 2003-07-06
BR0111800A (pt) 2003-05-27
US20070238756A1 (en) 2007-10-11
AP2002002703A0 (en) 2002-12-31
AU2005232303A1 (en) 2005-12-01
DZ3390A1 (fr) 2001-12-27
PL360493A1 (en) 2004-09-06
BG107385A (bg) 2003-09-30
NO20026038L (no) 2003-02-03
CZ20024069A3 (cs) 2004-02-18
EP1292300A1 (fr) 2003-03-19
MXPA02012763A (es) 2003-04-25
HRP20020994A2 (en) 2005-02-28
OA12295A (en) 2003-11-10
YU1703A (sh) 2006-03-03
HUP0301194A2 (hu) 2003-08-28
CA2413299A1 (fr) 2001-12-27
GB0014969D0 (en) 2000-08-09
AU2001264148A1 (en) 2002-01-02
EA200300036A1 (ru) 2003-04-24
EP2036554A1 (fr) 2009-03-18
AU2008212061A1 (en) 2008-10-02
KR20030019440A (ko) 2003-03-06
WO2001097808A1 (fr) 2001-12-27
ECSP024397A (es) 2003-02-06
NO20026038D0 (no) 2002-12-16
SK17832002A3 (en) 2004-10-05
JP2003535898A (ja) 2003-12-02
US7241756B2 (en) 2007-07-10
DE60137329D1 (de) 2009-02-26
IL188471A0 (en) 2008-03-20
ATE419850T1 (de) 2009-01-15
US20060205675A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
MA25820A1 (fr) Combinaisons d'inhibiteurs de peptidase iv de dipeptidyle et d'autres agents antidiabetiques pour le traitement du mellitus de diabete.
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
EP1769791A3 (fr) Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer
MY136707A (en) Thrombopoietin mimetics
CO5011115A1 (es) Compuestos y metodos quimioquina
ATE334718T1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
BRPI0416628A (pt) uso de compostos orgánicos
WO2003039454A3 (fr) Inhibiteurs de la beta-secretase et leurs procede d'utilisation
IS2619B (is) Notkun á fásykruhindra á þátt Xa í blöndu með storkuvarnar miðli til að meðhöndla slagæðasegarek.
TNSN01169A1 (fr) Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
NZ516290A (en) Substituted phenoxyacetic acids
EE04055B1 (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks, ja nende kasutamine
MA26899A1 (fr) PREPARATIONS CONTENANT UN MEDICAMENT GLUCOCORTICOiDE POUR LE TRAITEMENT DES MALADIES BRONCHOPULMONAIRES.
TNSN00106A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
WO2003020963A3 (fr) Proteines impliquees dans le diabete de type 2
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
FR2865736B1 (fr) Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
EP1251847A4 (fr) Nouvel emploi de la prodigiosine pour traiter le diabete
MA25753A1 (fr) Sel de thiazol idinedione pour le traitement du mellius du diabete
MA25509A1 (fr) Composition destinee au traitement de l'hepatite c
FR2849599B1 (fr) Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete